Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (355)	4/30/2001 4:43:26 PM
From: Salt'n'Peppa	Respond to of 513

AVANT Adds Depth to Senior Management Team Monday April 30, 4:30 pm Eastern Time SOURCE: AVANT Immunotherapeutics, Inc. AVANT Adds Depth to Senior Management Team With Appointment of Michael Henry, Vice President Business Development NEEDHAM, Mass., April 30 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today announced the appointment of Michael W. Henry as Vice President, Business Development. Mr. Henry joins the Company from the University of Massachusetts Medical School, where he was Senior Director, Licensing and Ventures. At UMass Medical School, Mr. Henry was responsible for negotiating a large number of research collaborations, out-licensing agreements and new company formation arrangements with biotechnology, pharmaceutical and medical device companies. At AVANT, Mr. Henry will be responsible for developing and implementing the Company's licensing and business development strategies. Previously, Mr. Henry has held business development and finance positions with US and Canadian based biotechnology companies. Mr. Henry received a B.S. from the University of Michigan, an M.S. and an MBA from the University of California, Berkeley. ``We are delighted that Mike has agreed to join us,'' said Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. ``Mike's extensive business development experience in structuring and negotiating licensing deals with biopharmaceutical and life science companies will be invaluable as AVANT advances its products through development.'' AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease. The company's most advanced therapeutic program focuses on compounds with the potential to inhibit inappropriate activation of the complement cascade, a vital part of the body's immune defense system. AVANT is also developing on its own a portfolio of oral vaccines aimed at protecting travelers from diseases endemic in developing areas, as well as a proprietary therapeutic vaccine for the management of cholesterol. Through corporate collaborations, the company is additionally developing a variety of infectious disease vaccines. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com.